Skip to main content

executive_appointment

Kalohexis Names TCR2 Ex-CEO Garry Menzel to Board

Kalohexis Names TCR2 Ex-CEO Garry Menzel to Board

Northbrook, Illinois – September 05, 2026 -- Kalohexis, Inc. has appointed Garry Menzel, Ph.D., to its Board of Directors, adding an executive who raised more than $500 million while leading oncology company TCR2 Therapeutics before its 2023 merger with Adaptimmune.

Menzel brings deal experience spanning $100 billion in biotech transactions

Menzel currently serves as an Operating Partner at Global Healthcare Opportunities (GHO) Capital, a European healthcare-focused private equity firm. He previously worked as an investment banker at Goldman Sachs and Credit Suisse, where he led global biotechnology franchises and worked on transactions totaling more than $100 billion, including IPOs and M&A deals.

Wellinks Names Ex-Teladoc COO, UConn Health CEO to Board

Wellinks Names Ex-Teladoc COO, UConn Health CEO to Board

New Haven, Conn. – September 04, 2026 -- Wellinks, a virtual-first cardiopulmonary care company, has appointed Andrew Agwunobi, MD, MBA, and Mike Waters to its Board of Directors while adding three vice presidents to its management team, the company said.

Former Teladoc COO Mike Waters joins Wellinks board with digital health portfolio

Waters, who spent more than two decades in strategic operations and previously served as Chief Operating Officer of Teladoc Health, also brings 15-plus years from Providence Health, where he was Executive Vice President and Chief Executive of its Ambulatory Care Network. He currently holds board roles across six digital health companies, including Chair positions at Ieso and Brook Health.